Suppr超能文献

头颈部鳞状细胞癌切缘无肿瘤的治疗意义

Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma.

作者信息

Backes Clara, Bier Henning, Knopf Andreas

机构信息

Otorhinolaryngology/Head and Neck Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 München, Germany.

出版信息

Oncotarget. 2017 Sep 16;8(48):84320-84328. doi: 10.18632/oncotarget.21035. eCollection 2017 Oct 13.

Abstract

OBJECTIVES

The resection status is one of the most important prognostic factors for patients with head and neck squamous cell carcinoma (HNSCC) concerning overall survival (OS) and recurrence free interval (RFI). To assess whether therapy concepts changed depending on different resection margins and extracapsular extension, OS and RFI data were set into clinical context.

METHODS

All HNSCC patients who underwent head and neck surgery with/without adjuvant therapy (n=534) were selected over a ten-year period (2001-2011). Clinical parameters and survival data were collected retrospectively and histopathological analysis of tumor free margins and extracapsular extension were done.

RESULTS

Patients with microscopic resection showed mean OS/RFI of 95/96 months. OS/RFI decreased in microscopic macroscopic (56/58 and 35/39 months) as well as in unclear resection margins (63/60 months). Patients with extracapsular extension, microscopic - resection as well as patients with resection after follow up resection demonstrated therapy escalation by adjuvant (chemo-) radiation.

CONCLUSIONS

Insufficient surgical margins and extracapsular extension are main risks for a reduced overall and recurrence free survival. Although there is no measure to prevent positive extracapsular extension, clear margins at first pass protect patients from adjuvant therapy escalation.

摘要

目的

对于头颈部鳞状细胞癌(HNSCC)患者而言,切除状态是关乎总生存期(OS)和无复发生存期(RFI)的最重要预后因素之一。为评估治疗方案是否因不同的切除切缘和包膜外扩展情况而改变,将OS和RFI数据纳入临床背景进行分析。

方法

选取在十年期间(2001 - 2011年)接受了头颈外科手术(无论有无辅助治疗)的所有HNSCC患者(n = 534)。回顾性收集临床参数和生存数据,并对无瘤切缘和包膜外扩展进行组织病理学分析。

结果

显微镜下切除的患者平均OS/RFI为95/96个月。显微镜下/宏观切缘阳性(56/58个月和35/39个月)以及切缘不明确(63/60个月)的患者OS/RFI降低。有包膜外扩展、显微镜下/宏观切缘阳性的患者以及随访切除后切缘阳性的患者通过辅助(化疗)放疗实现了治疗升级。

结论

手术切缘不足和包膜外扩展是总生存期和无复发生存期降低的主要风险因素。尽管没有措施可预防包膜外扩展阳性,但初次手术切缘阴性可使患者避免辅助治疗升级。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac61/5663598/c7ee94a0b04b/oncotarget-08-84320-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验